

Bulletin from the Annual General Meeting of CellaVision AB (publ) held on May 6, 2015

CellaVision AB (publ) held its Annual General Meeting today, 6 May 2015, in Lund. The meeting resolved upon the following:

- Payment of dividend in the amount of SEK 1 per share with 8 May 2015 as record date, meaning that payment is expected to be made on 13 May 2015.
- Discharge from liability for the members of the Board of Directors and the President and CEO.
- Re-election of Lars Gatenbeck, Christer Fåhraeus, Roger Johanson, Torbjörn Kronander, Anna Malm Bernsten and Niklas Prager as members of the Board of Directors. Election of Åsa Hedin as a new member of the Board of Directors. Re-election of the auditor.
- Resolution on remuneration for the members of the Board of Directors and the auditor.
- Resolution on an incentive program for the company management. Those eligible are the CEO and members of the executive management.

More detailed information concerning the resolutions passed at the general meeting of shareholders is available in Swedish only.

CEO Zlatko Rihter's address to the meeting is available at the Investor pages at CellaVision's website (Swedish).

For more information, please contact:

Lars Gatenbeck, Chairman of the Board, CellaVision AB.

Phone: +46 70 535 44 44, e-mail: lars.gatenbeck@lifemedical.se

Zlatko Rihter, CEO, CellaVision AB.

Phone: +46 733 62 11 06, e-mail: zlatko.rihter@cellavision.com

About CellaVision

CellaVision is an innovative, global medical technology company that develops and sells its own leading systems for routine analysis of blood and other body fluids in health care services. The products rationalize manual laboratory work, and secure and support effective workflows and skills development within and between hospitals. The company has leading-edge expertise in image analysis, artificial intelligence and automated microscopy. In most countries sales are via global partners. Products are sold directly in the Nordic countries and via subsidiaries in the US, Canada and Japan. In 2014 sales were SEK 217 million and sales continue to increase, with a growth target of at least 15 % per year over an economic cycle. CellaVision's registered office is in Lund, Sweden. The share is listed on the Nasdaq OMX Stockholm, Small Cap list. Read more at www.cellavision.com.

Publication

The information in this press release comprises such information as CellaVision AB (publ) is required to publish in accordance with the Securities Market Act and/or the Financial Instruments Trading Act. This information was released for public disclosure on May 7, 2015 at 08:20 CET.